Safety and toxicology tested.
To assess the safety of Sonadil®, a battery of acute and sub-acute toxicity studies were conducted in various animal models according to the OECD test guidelines. The acute oral LD50 of Aflapin was greater than 5000 mg/kg in female Sprague Dawley (SD) rats. Acute dermal LD50 of Sonadil® - in was greater than 2000 mg/kg in SD rats. A primary dermal irritation study conducted using New Zealand White rabbits indicated that Sonadil® is non-irritating to skin. A repeat dose 28-day sub-acute oral toxicity study in SD rats demonstrated no significant signs of toxicity. Various evaluations including hematology, clinical chemistry, gross necropsy, and histopathology did not show any significant adverse changes. The NOAEL of Sonadil® was found to be greater than 2500 mg/kg body weight. These studies demonstrate broad spectrum safety of Sonadil® in animal models.
The Major application of Sonadil®
- Joint pain
- Fractured bone - anti inflammation
- Post surgery
- Cancer patient
- Fever
Clinical Studies on Sonadil - Aflapin®
- Cellular and molecular mechanisms of anti-inflammatory effect of Aflapin: a novel Boswellia serrata extract
- A Double Blind, Randomized, Placebo Controlled Clinical Study Evaluates the Early Efficacy of Aflapin® in Subjects with Osteoarthritis of Knee
- Comparative Efficacy and Tolerability of 5-Loxin® and Aflapin® Against Osteoarthritis of the Knee: A Double Blind, Randomized, Placebo Controlled Clinical Study
- Safety and toxicological evaluation of Aflapin®: A novel Boswellia-derived anti-inflammatory product
